Online first
Expert opinion
Published online: 2025-03-07
Interdisciplinary expert team statement on the treatment of multi-bed atherosclerotic disease — endorsed by Polish Cardiac Society, Polish Lipid Association, Polish Society of Diabetology, Polish Neurological Society, Polish Society of Nephrology
Pubmed: 40066957
Abstract
Atherosclerosis is a systemic disease and involves not only the coronary vessels but also occurs in other vascular beds (e.g., cervical, cerebral, and peripheral vessels), increasing cardiovascular risk. One of the causes of atherosclerosis is lipid disorders. In addition, other diseases, such as diabetes, chronic kidney disease, or familial hypercholesterolemia, accelerate the development of multi-bed (multilevel) atherosclerosis. So far, such patients are often treated by physicians of various specialties, and in our country, there is no integrated system for managing these patients and their further treatment. This frequently results in the inability to achieve the therapeutic goals for low-density lipoprotein cholesterol set by the guidelines despite the availability of modern therapy for the treatment of lipid disorders in our country. The presented expert position paper postulates modification of the treatment of patients with multi-bed atherosclerosis by strengthening cooperation between physicians of many specialties (cardiologists, diabetologists, nephrologists, vascular surgeons, pediatricians, etc.) in order to improve the effectiveness of treatment and better educate the medical community and the treated patients.
Keywords: interdisciplinary managementLDL cholesterolmulti-bed atherosclerosis
References
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
- Mensah GA, Fuster V, Murray CJL, et al. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol. 2023; 82(25): 2350–2473.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
- Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021; 17(6): 1447–1547.
- Solnica B, Sygitowicz G, Sitkiewicz D, et al. 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci. 2024; 20(2): 357–374.
- Filipiak KJ, Babkowski MC, Cameli M, et al. TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice. Cardiol J. 2022; 29(5): 730–738.
- NFZ o zdrowiu — choroba niedokrwienna serca. https://ezdrowie.gov.pl/pobierz/nfz_o_zdrowiu_choroba_niedokrwienna_serca_v1 (accessed: January 9, 2025).
- NFZ o zdrowiu — udar niedokrwienny mózgu. https://ezdrowie.gov.pl/pobierz/udar-pdf (accessed: January 9, 2025).
- Banach M, Surma S, Toth PP. 2023: The year in cardiovascular disease — the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? Arch Med Sci. 2023; 19(6): 1602–1615.
- Vrablik M, Seifert B, Parkhomenko A, et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis. 2021; 334: 66–75.
- Nowowiejska-Wiewióra A, Wita K, Mędrala Z, et al. Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program. Kardiol Pol. 2023; 81(4): 359–365.
- Banach M, Penson PE, Vrablik M, et al. et al.. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021; 166: 105499.
- Byrne RA, Rossello X, Coughlan JJ, et al. et al.. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38): 3720–3826.
- Jankowski P, Kosior DA, Sowa P, et al. Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey. Cardiol J. 2020; 27(5): 533–540.
- Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023; 29: 100624.
- Mitkowski P, Witkowski A, Stępińska J, et al. Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions. Kardiol Pol. 2023; 81(7–8): 818–823.
- Abtan J, Bhatt DL, Elbez Y, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295(2): 180–189.
- Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol. 1992; 49(8): 857–863.
- Marx N, Federici M, Schütt K, et al. et al.. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043–4140.
- Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733): 2215–2222.
- Katsiki N, Banach M, Mikhailidis DP. Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient! Arch Med Sci. 2019; 15(6): 1357–1364.
- Banach M, Surma S, Reiner Z, et al. Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022). Cardiovasc Diabetol. 2022; 21(1): 263.
- Dyrbus K, Gasior M, Desperak P, et al. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes - Data from the TERCET registry with 19,287 patients. Pharmacol Res. 2019; 139: 460–466.
- Dąbrowski M. Wytyczne Polskiego Towarzystwa Diabetologicznego 2024, czyli ochrona sercowo-naczyniowo-nerkowa z metaboliką w tle. Lekarz POZ. 2024; 10(1): 1–11.
- Błażejewska-Hyżorek B, Czernuszenko A, Członkowska A, et al. Wytyczne postępowania w udarze mózgu [article in Polish]. Pol Przegl Neurol. 2019; 15(Suppl A): 1–156.
- Dawson J, Béjot Y, Christensen LM, et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022; 7(3): I–II.
- Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021; 52(7): e364–e467.
- Labuz-Roszak B, Banach M, Skrzypek M, et al. Secondary stroke prevention in polish adults: Results from the LIPIDOGRAM2015 study. J Clin Med. 2021; 10(19): 4472.
- Giugliano RP, Pedersen TR, Saver JL, et al. Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke. 2020; 51(5): 1546–1554.
- Jukema JW, Szarek M, Zijlstra LE, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019; 74(9): 1167–1176.
- Sabouret P, Angoulvant D, Cannon CP, et al. Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: Is there still a matter of debate? Eur Heart J Open. 2022; 2(4): oeac038.
- Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007; 2007(4): CD000123.
- Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019; 393(10170): 407–415.
- Aboyans V, Ricco JB, Bartelink MEL, et al. et al.. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO). The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763–816.
- Naylor R, Rantner B, Ancetti S, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2023; 65(1): 7–111.
- Gąsior M, Wita K, Buszman P, et al. Managed Care after Acute Myocardial Infarction (MC-AMI) improves prognosis in AMI survivors with pre-existing heart failure: A propensity score matching analysis of Polish nationwide program of comprehensive post-MI care. Kardiol Pol. 2022; 80(3): 293–301.
- Skeik N, Nowariak ME, Smith JE, et al. Lipid-lowering therapies in peripheral artery disease: A review. Vasc Med. 2021; 26(1): 71–80.
- Pajak A, Szafraniec K, Polak M, et al. Prevalence of familial hypercholesterolemia: A meta-analysis of six large, observational, population-based studies in Poland. Arch Med Sci. 2016; 12(4): 687–696.
- Dyrbuś K, Gąsior M, Desperak P, et al. The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals. Atherosclerosis. 2019; 288: 33–41.
- Chlebus K, Cybulska B, Gruchała M, et al. Prevalence, diagnosis, and treatment of familial hypercholesterolaemia in outpatient practices in Poland. Kardiol Pol. 2018; 76(6): 960–967.
- Lewek J, Sosnowska B, Gach A, et al. Clinical reality and challenges with familial hypercholesterolemia patients management. 2024 results from the Regional Center for Rare Diseases (RCRD) Registry in Poland. ESC Congress 2024. London, 2024.
- Opieka koordynowana nad pacjentem z przewlekłą chorobą nerek. Praca zbiorowa pod redakcją prof. dr. hab. n. med. Ryszarda Gellerta. http://www.izbamedpol.pl/wp-content/uploads/2019/03/opieka_koordynowana_raport_2019.pdf (accessed: January 9, 2025).
- Rysz-Górzyńska M, Banach M. Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients. Arch Med Sci. 2016; 12(4): 844–849.
- Rysz J, Gluba-Brzózka A, Banach M, et al. Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. Int Urol Nephrol. 2015; 47(5): 805–813.
- Katsiki N, Mikhailidis DP, Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opin Pharmacother. 2019; 20(16): 2007–2017.
- Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovasc Res. 2019; 115(3): e26–e31.
- https://bip.aotm.gov.pl/assets/files/zlecenia_mz/2024/055/RPT/2024%2002%2022%20OT%20opracowanie%20zmiany%20B.101%20627.pdf (accessed: January 9, 2025).
- Ray KK, Pillas D, Hadjiphilippou S, et al. Premature morbidity and mortality associated with potentially undiagnosed familial hypercholesterolemia in the general population. Am J Prev Cardiol. 2023; 15: 100580.
- Allahyari A, Jernberg T, Hagström E, et al. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: A simulation study. Eur Heart J. 2020; 41(40): 3900–3909.
- Dyrbuś K, Gąsior M, Penson PE, et al. Extreme cardiovascular risk-do we need a new risk category? Eur Heart J. 2022; 43(19): 1784–1786.
- Lewek J, Niedziela J, Desperak P, et al. Intensive statin therapy versus upfront combination therapy of statin and ezetimibe in patients with acute coronary syndrome: A propensity score matching analysis based on the PL-ACS data. J Am Heart Assoc. 2023 ; 12(18): e030414.
- Banach M, Reiner Z, Cicero AFG, et al. 2022: The year in cardiovascular disease - the year of upfront lipid lowering combination therapy. Arch Med Sci. 2022; 18(6): 1429–1434.
- Lee SJ, Joo JH, Park S, et al. Combination lipid-lowering therapy in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2023; 82(5): 401–410.
- Cybulska B, Kłosiewicz-Latoszek L, Penson PE, et al. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Prog Cardiovasc Dis. 2021; 67: 65–74.
- Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390(10106): 1962–1971.
- Gaba P, O'Donoghue ML, Park JG, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: An analysis of FOURIER-OLE. Circulation. 2023; 147(16): 1192–1203.
- Zimerman A, O'Donoghue M, Ran X, et al. Abstract 14714: Long-term neurocognitive safety of LDL-C lowering with evolocumab: Open-label extension data from FOURIER. Circulation. 2023; 148(Suppl 1): A14714.
- Wright RS, Koenig W, Landmesser U, et al. Safety and tolerability of inclisiran for Treatment of hypercholesterolemia in 7 clinical trials. J Am Coll Cardiol. 2023; 82(24): 2251–2261.
